Amiodarone 300 mg IV push would be administered for which rhythm in the ACLS algorithms?

Choice A rationale Amiodarone is a class III antiarrhythmic that slows conduction and prolongs the refractory period in myocardial tissue. In the ACLS algorithm for cardiac arrest, a 300 mg bolus is indicated for pulseless ventricular tachycardia or ventricular fibrillation that is unresponsive to initial defibrillation and vasopressors. It works by blocking potassium channels, which helps to stabilize the electrical environment of the heart and facilitates the return of a perfusing rhythm during resuscitation. Choice B rationale Symptomatic bradycardia is primarily treated with atropine, which blocks vagal effects on the sinoatrial node to increase the heart rate. If atropine is ineffective, pacing or infusions of dopamine or epinephrine are considered. Amiodarone is contraindicated in this scenario because its primary mechanism involves slowing the heart rate and conduction. Administering an antiarrhythmic like amiodarone to a patient who is already bradycardic would likely worsen the condition and lead to asystole. Choice C rationale Asystole is a state of no electrical or mechanical activity in the heart. The treatment priorities for asystole are high-quality CPR and the administration of epinephrine to increase coronary perfusion pressure. Amiodarone has no role in the treatment of asystole because there is no organized or disorganized electrical rhythm for the drug to suppress or modify. Using an antiarrhythmic on a heart with no electrical activity provides no physiological benefit to the patient. Choice D rationale For stable supraventricular tachycardia, the initial interventions include vagal maneuvers followed by adenosine to briefly block the atrioventricular node. While amiodarone can be used for certain stable atrial arrhythmias, the specific dose of 300 mg IV push is reserved for pulseless arrest scenarios. In a stable patient with a pulse, amiodarone is typically administered as an infusion over several minutes to avoid profound hypotension and other severe cardiovascular side effects.